XIYOUJI QINGZHI CAPSULE — Class I drug recall D-1250-2014
Terminated recall by Dolphin Intertrade Corporation, reported 2014-04-30, distributed nationwide. Marketed without an Approved NDA/ANDA: Products found to contain undeclared sibutramine. Sibutramine was remov
| Recall number | D-1250-2014 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Dolphin Intertrade Corporation, Miami, FL, United States |
| Recall initiated | 2013-05-20 |
| Classified | 2014-04-18 |
| Reported by FDA | 2014-04-30 |
| Terminated | 2016-06-29 |
| Distributed | Nationwide (US) |
| Quantity | 8 bottles |
| Reason classes | undeclared allergen, unapproved product |
Product
XIYOUJI QINGZHI CAPSULE, 300mg, 20 count box
Reason for recall
Marketed without an Approved NDA/ANDA: Products found to contain undeclared sibutramine. Sibutramine was removed from the U.S. market for safety reasons, making these products unapproved new drugs.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1250-2014. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.